Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.

CEO

Tord Labuda

Employees

Country

Sweden

ISIN

SE0030587168

Listings

0 Comments

Share your thoughts

FAQs

What is Alzinova stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Alzinova stocks are traded under the ticker ALZ-BT-UN.ST.

When is the next Alzinova earnings date?▼

Alzinova is going to release the next earnings report on November 12, 2026.

What is Alzinova revenue for the last year?▼

Alzinova revenue for the last year amounts to 0 SEK.

What is Alzinova net income for the last year?▼

ALZ-BT-UN.ST net income for the last year is -26.27M SEK.

How many employees does Alzinova have?▼

As of November 3, 2026, the company has 7 employees.

In which sector is Alzinova located?▼

Alzinova operates in the Health & Wellness sector.

When did Alzinova complete a stock split?▼

Alzinova has not had any recent stock splits.

Where is Alzinova headquartered?▼

Alzinova is headquartered in Mölndal, Sweden.